Findings show potential for new lipid-based delivery formulations as a platform technology for immunizationPhiladelphia, PA, ...

Shares of Prime Medicine (NASDAQ: PRME) are surging on Thursday. The move up comes as the S&P 500 and Nasdaq Composite gained ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

News of a fresh investigational program was putting some zip into the shares of gene-editing company Prime Medicine (NASDAQ: ...

Deficiency and insufficiency of vitamin D is a global concern, affecting a vast proportion of the Indian population as well; ...

Beam Therapeutics reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. See why I ...

DNA delivery using lipid nanoparticles results in severe toxicity in mice. However, we find that the incorporation of endogenous anti-inflammatory lipids into the lipid nanoparticles mitigates ...

Curia will expand its Glasgow, UK facility and offers updates on the ongoing expansion to its Albuquerque, NM facility.

Immunotherapy has emerged as one of the major options for cancer treatment in the past decade. With the successful application of immune checkpoint inhibitors and the introduction of immune regulatory ...

The round will fund a “one-and-done” treatment for a rare kidney condition that its CEO says can address concerns patients ...

Prime Editing has potential to be best-in-class approach for AATD -- -- Previously undisclosed program now emerging from within liver platform; leverages proprietary, universal liver LNP -- -- High ...

Curia Global, Inc. (Curia), a leading contract research, development and manufacturing organization, today announced expansion plans to its Glasgow, UK ...